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Introduction
Metabolic syndrome (MS) is characterized by the clustering of 
risk factors related to insulin resistance and is associated with an 
increased rate of cardiovascular disease and all-cause mortality.
1-4) 
Several studies have established the significance of non-high density 
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Background and Objectives: Non-high density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) are markers of athero-
sclerotic risk and predictors of cardiovascular events. The aim of this study was to evaluate clinical impact of non-HDL-C and ApoB on clini-
cal outcomes in metabolic syndrome (MS) patients with acute myocardial infarction (AMI) undergoing percuatneous coronary intervetion.
Subjects and Methods: We analyzed 470 MS patients (64.4±12.0 years, 53.6% male) with AMI who were followed-up for 12-month after 
percutaneous coronary intervention (PCI) from December 2005 to January 2008 in a single center. These patients were divided into 2 
groups based on median values of non-HDL-C and ApoB. We studied their baseline and follow-up relation with 12-month clinical out-
comes, all-cause death and major adverse cardiac events (MACE).
Results: Mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/dL and 99.3±29.0 mg/dL respectively. During 12-month fol-
low-up 32 MACE (6.8%) and 12 deaths (2.5%) occurred. We observed significant correlation between non-HDL-C and ApoB. Twelve-month 
MACE and all-cause death after PCI showed no significant relation as non-HDL-C or ApoB levels increased. Follow-up patients (n=306, rate 
65%) also did not show significant relation with clinical outcomes. Twelve-month MACE decreased as non-HDL-C and ApoB reduction 
rates increased. 
Conclusion: There was no significant association between higher non-HDL-C or ApoB and 12-month clinical outcomes in MS patients with 
AMI undergoing PCI. ApoB was found to be a better predictor of 12-month MACE than non-HDL-C based on their reduction rates. (Korean 
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lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (ApoB) 
as predictive factors for coronary artery disease (CAD) and their as-
sociation with excess cardiovascular morbidity and mortality.
2)3) Non-
HDL-C measurement (calculated as total cholesterol minus HDL-C) 
provides a single index of all the atherogenic ApoB containing li-
poproteins - low density lipoprotein, very low density lipoprotein, in-
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termediate-density lipoprotein and other remnant lipoproteins. In 
2001, the National Cholesterol Education Program (NCEP) Adult Treat-
ment Panel (ATP) III provided a new definition for MS and this is bas-
ed on simple clinical criteria and is considered as a prognostic indi-
cator of vascular risk in patients with no overt CAD.
1-5) Most recently, 
in 2005, American Heart Association/National Heart Lung and Blood 
Institute (AHA/NHLBI) presented new criteria modified from NCEP-
ATP III criteria.
6) 
Prevention of cardiovascular events in MS patients is the main 
theme of cardiology today. Therefore, the aim of this study was to in-
vestigate the association of non-HDL-C and ApoB with clinical out-
comes in MS patients with acute myocardial infarction (AMI) after 
percuatneous coronary intervetion (PCI).
Subjects and Methods
This retrospective study was carried out at The Heart Center of 
National University Hospital, Korea. The study was conducted ac-
cording to the declaration of Helsinki. Informed written consent for 
the procedures was obtained from all patients and permission to 
carry out the study had been sought from the hospital authorities 
(institutional review board number 05-49 and I-2008-01-009).
Korea Acute Myocardial Infarction Registry
The Korea Acute Myocardial Infarction Registry is a prospective, 
multicenter, observational registry designed to examine current epi-
demiology in hospital management and outcome of patients with 
AMI in Korea for the commemoration of the 50th anniversary of the 
Korean Circulation Society. The registry included 52 community and 
university hospitals for primary PCI. Data was collected at each site by 
a well-trained study coordinator based on standardized protocol.
7)8)
Study population
Patients with AMI from December 2005 to January 2008 were 
assessed by the diagnostic criteria of MS and followed up for 12 
months. ST-segment elevation myocardial infarction (STEMI) and 
non-STEMI patients who did not fulfill the criteria of MS were exclud-
ed from this study. As a result, a total number of 470 patients were 
selected for this study, mean age was 64.4±12.0 years and 53.6% 
patients were male (n=252). 
Study definitions and clinical endpoints  
Patients’ medical documents were used to note the demographic 
data, clinical characteristics and relevant laboratory results. Diabe-
tes mellitus (DM) was defined as use of oral hypoglycaemic agent or 
insulin to lower blood glucose levels. Hyperlipidemia was defined 
as total cholesterol >200 mg/dL or treatment with a lipid-lowering 
agent. CAD was defined as history of myocardial infarction (MI), 
revascularization procedure or obstructive CAD. A final diagnosis of 
AMI was made according to European Society of Cardiology/Ameri-
can College of Cardiology diagnostic criteria of AMI.
9) 
Peripheral blood samples were obtained on admission using di-
rect venipuncture. Blood samples were centrifused and serum was 
removed and stored at -70°C until the assay for sugar and proteins 
could be performed. Blood samples for high sensitivity-C-reactive pro-
tein (hs-CRP) were obtained on admission and were analyzed turbi-
dimetrically with sheep antibodies against human CRP; this has 
been validated against the Dade Behring method. Absolute creatine 
kinase-MB levels were determined by radioimmunoassay (Dade Be-
hring, Inc., Miami, FL, USA). Cardiac specific troponin I levels were 
measured by a paramagnetic particle, chemiluminescent immuno-
enzymatic assay (Beckham, Coulter, Inc. Fullerton, CA, USA). Twelve-
hour fasting serum levels of total cholesterol, triglyceride, low and 
high density lipoprotein-cholesterol, and ApoB were measured by 
standard enzymatic methods. Non-HDL-C was calculated as total 
cholesterol minus high density lipoprotein-cholesterol (HDL-C). The 
selected patients were divided into two groups according to the me-
dian value of baseline non-HDL-C, group 1 ≤138 mg/dL, n=234 and 
group 2 >138 mg/dL, n=236. In another set, these patients were di-
vided into two groups based on median value of baseline ApoB, 
group 1 ≤96.5 mg/dL, n=235 and group 2 >96.5 mg/dL, n=235. 
Two-dimensional echocardiography was performed in all pa-
tients and left ventricular ejection fraction was assessed by Simp-
sons biplanar method. The morphology in coronary angiography 
was classified by criteria of American College of Cardiology/Ameri-
can Heart Association (ACC/AHA).
10) The degree of coronary flow was 
classified by Thrombolysis in Myocardial Infarction score.
11) Pres-
ence of left main coronary artery stenosis was defined as a luminal 
stenosis ≥50%. Multivessel disease was defined as the presence of 
a lesion with >50% stenosis in a non-infarct related coronary ar-
tery. All patients were administered loading doses of aspirin 325 
mg and clopidogrel 300-600 mg before PCI. On admission antico-
agulation was performed with un-fractionated heparin 5000 IU IV 
bolus followed by 24000 IU over 24 hours. During PCI 5000-7500 IU 
IV bolus is given followed by 1000 IU an hour later, then additional 
heparin to achieve an activated clotting time of 250-350 seconds. 
After the procedure, aspirin 100-200 mg (once daily) was prescribed 
indefinitely. Clopidogrel was prescribed continuously for 1 year. 
The clinical outcomes studied were 1) 12-month major adverse 
cardiac events (MACE) and 2) 12-month all-cause death. MACE in-
cluded all-cause death, non-fatal MI and target vessel revasculariz-
ation. All data were recorded on a standardized, electronic, web based 
registry at http://www.kamir.or.kr.
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criteria. Central obesity was defined as waist circumference >90 cm 
in men or >80 cm in women by modified ATP III guideline that WHO-
Western Pacific Region and International Association for the Study 
of Obesity presented for Asian populations in 2000. The presence of 
MS was analyzed considering the presence of the following crite-
ria: 1) central obesity: waist circumference >90 cm (men), >80 cm 
(women), 2) a fasting triglyceride level ≥150 mg/dL, 3) reduced HDL-
C: <40 mg/dL (men), <50 mg/dL (women), 4) hypertension: blood 
pressure ≥130/85 mm Hg or taking antihypertensive medication, 5) 
impaired fasting glucose (IFG): fasting glucose ≥110 mg/dL, or tak-
ing anti-diabetic medication or past history of type 2 DM. Patients 
were considered to have MS in the presence of ≥3 of the above cri-
teria according to the definition proposed by AHA/NHLBI. Although 
AHA/NHLBI guideline recommended the definition of IFG at/above 
100 mg/dL, our study adopted NCEP-ATP III guideline.
6) 
This set of MS patients were followed up for 10-15 months (n= 
306, follow-up rate 65.1%) with a mean follow-up at 12 months. 
They were also divided into two groups based on their non-HDL-C 
and ApoB follow-up levels and clinical outcomes were also studi-
ed. To evaluate the effect of after treatment reduction of non-HDL-
C and ApoB on clinical outcomes we divided the same subset of 
patients into three groups based on their reduction percentage-
group A (reference group) included reduction rate 0-10% (n=16 in 
non-HDL-C arm and n=23 in ApoB arm), group B included 10-30% 
reduction (n=30 in non-HDL-C arm and n=64 in ApoB arm) and 
group C included >30% (n=158 in non-HDL-C arm and n=117 in 
ApoB arm). We also studied patients who had higher follow-up lev-
els of non-HDL-C and ApoB than the baseline levels (n=102) so that 
we could compare the impact of their reduction and increase on 
clinical outcomes. 
Statistical analysis
Statistical Package for the Social Sciences (SPSS) 17.0 for windows 
(SPSS Inc., Chicago, IL, USA) was used for all analysis. Continuous 
variables were presented as mean±SD. Comparisons were conduct-
ed by Student’s t-test. Discrete variables were presented as percent-
ages and frequencies; comparisons were conducted by chi-square/
Fischer’s exact statistics. All statistical tests were 2-tailed, with sta-
tistical significance defined as p<0.05. To estimate the degree of re-
lationship between the two quantitative non-parametric variables 
we used Pearson’s correlation test or Spearman’s rank correlation 
test. We used linear-by-linear association to evaluate the relation 
between a parameter and 12-month clinical outcomes. 
Cox proportional hazard analysis was performed to identify a 
model with independent predictive factors with a determination of 
hazard ratio and its 95% confidence interval for each variable in the 
model. A cut off p<0.2 in univariate analysis for end points and oth-
er variables that have been reported to be associated with prognosis 
of patients with AMI were entered into the Cox model. The vari-
ables included were age, gender, systolic blood pressure, hyperten-
sion, history of CAD, serum creatinine, total cholesterol, triglyceride, 
ApoB, clinical presentation with STEMI, hs-CRP, N-terminal pro-
brain natrieuretic peptide, HDL-C, left main involvement, ACC/AHA 
lesion type C, in-hospital complications, and use of beta-blocker, 
calcium-channel blocker and statin for baseline non-HDL-C. The 
variables included in baseline ApoB Cox model were age, gender, 
systolic blood pressure, hypertension, clinical presentation with 
STEMI, serum creatinine, total cholesterol, triglyceride, hs-CRP, HDL-C, 
non-HDL-C, left main involvement, in-hospital complications, and 
statin use. The number of 12-month deaths was very small, n=12 
(2.5%) so we limited our analysis to MACE. 
Results 
A total number of 470 MS patients were selected for this study 
with mean age 64.4±12.0 years and 53.6% were men (n=252). The 
mean values of baseline non-HDL-C and ApoB were 141.2±43.1 mg/
dL and 99.3±29.0 mg/dL respectively. These patients were followed 
up for 12-month (n=306, follow-up rate 65%). 
Baseline characteristics, coronary angiographic findings and 
procedural results
As shown in Table 1, patients in group 2 i.e. with higher non-HDL-
C (>138 mg/dL) tended to be younger. They showed increased sys-
tolic blood pressure, total cholesterol, triglyceride and ApoB whereas 
previous history of hypertension, serum creatinine, hs-CRP, left main 
involvement, and in-hospital complications decreased. Frequency 
of STEMI and use of calcium-channel blocker was lower and use of 
statin was higher in group 2. As shown in Table 2, patients in group 
2, with higher ApoB (>96.5 mg/dL) levels were younger, and 
showed increased systolic blood pressure, total cholesterol, triglyc-
eride and non-HDL-C whereas serum creatinine, hs-CRP, left main 
involvement and in-hospital complications decreased. The use of 
statin was more frequently observed in group 2. 
Clinical outcomes and major adverse cardiac events
During 12-month follow-up 32 MACE (6.8%) and 12 deaths (2.5%) 
occurred. Pearson’s simple correlation analysis revealed a signifi-
cant correlation between baseline non-HDL-C and ApoB (r=0.655, 
p<0.001) and Spearman’s rank test also showed a significant cor-
relation between them (r=0.655, p<0.001). 
Twelve-month MACE and death after PCI showed no signifi-
cance association between non-HDL-C baseline groups: 12-month 
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0.595, linear p=0.714 and adjusted p=0.516; and 12-month death, 
2.56% in group 1 vs. 2.54% in group 2 with unadjusted p=0.486, li-
near p=0.99 and adjusted p=0.716 as shown in Table 3. Also, 12- 
month MACE and death after PCI showed no significance associa-
tion between ApoB baseline groups: 12-month MACE, 6.8% in 
both groups with unadjusted p=0.698, linear p=0.958 and adjusted 
Table 1. Baseline clinical characteristics, coronary angiographic findings and procedural results according to the levels of non-high density lipoprotein-
cholesterol
Variables Group 1 (≤138 mg/dL), n=234 Group 2 (>138 mg/dL), n=236 p
Age (years) 65.4±11.4 63.3±12.4 0.058
Male gender, n (%) 133 (56.8) 119 (50.4) 0.163
Waist circumference (cm) 90.1±7.8 90.8±6.7 0.271
Body weight (kg) 65.5±12.7 66.4±11.8 0.471
Systolic blood pressure (mm Hg) 127.5±32.9 136.8±25.5 0.001
Heart rate (beats/min) 75.6±21.4 77.9±18.4 0.204
Left ventricular ejection fraction (%) 53.4±12.5 55.1±11.7 0.238
Killip class >1, n (%) 61 (26.1) 58 (24.6) 0.71
Smoking history, n (%) 76 (32.5) 94 (39.8) 0.38
Past history, n (%)
    Hypertension 189 (80.8) 168 (71.2) 0.015
    Diabetes mellitus 129 (55.1) 141 (59.7) 0.311
    Coronary artery disease 43 (18.4) 30 (12.7) 0.09
    Previous hyperlipidemia  10 (4.3) 6 (2.5) 0.301
Clinical presentation, n (%)
    ST-segment elevation myocardial infarction 152 (64.9) 128 (54.2) 0.011
Laboratory findings
    Glucose (mg/dL) 209.9±93.4 209.6±96.9 0.974
    Creatinine (mg/dL) 1.3±1.5 1.0±0.4 0.001
    Total cholesterol (mg/dL) 149.8±26.7 214.8±32.7 <0.001
    Triglycerides (mg/dL) 138.8±122.8 183.3±106.8 <0.001
    Apolipoprotein B (mg/dL) 81.5±20.8 116.8±24.9 <0.001
    High sensitivity C-reactive protein (mg/dL) 3.3±4.6 2.5±4.2 0.045
    N terminal pro-brain natrieuretic peptide (pg/mL) 3827.9±6805.8 2989.6±5469.3 0.146
    High density lipoprotein-cholesterol (mg/dL) 38.5±41.5 40.2±42.6 0.145
    Creatine kinase-MB (U/L) 100.3±103.1 106.8±103.8 0.498
    Troponin-I (ng/mL) 48.7±63.7 49.8±151.7 0.918
Angiographic findings, n (%)
    Multivessel involvement 80 (34.2) 87 (36.8) 0.463
    Left main involvement 18 (7.7) 4 (1.7) 0.002
    ACC/AHA lesion type C 57 (24.3) 71 (30.1) 0.198
    In-hospital complications 56 (23.9) 27 (11.5) <0.001
Discharge medications, n (%)
    Aspirin 223 (95.3) 226 (95.7) 0.459
    Clopidogrel 213 (91.0) 217 (91.9) 0.474
    Beta-blocker 184 (78.6) 197 (83.5) 0.119
    Calcium-channel blocker 35 (15.5) 19 (8.0) 0.021
    Anti-diabetic 101 (43.2) 102 (43.2) 0.893
    Statin 166 (70.9) 204 (86.4) <0.001
Data are expressed as number (percentage), or mean±SD. ACC/AHA: American College of Cardiology/American Heart Association323 Khurshid Ahmed, et al.
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p=0.675; 12-month death, 2.5% in each group with unadjusted p= 
0.712, linear p=0.975 and adjusted p=0.919 as shown in Table 4.
Cox regression analysis of baseline non-HDL-C and ApoB groups 
showed no significant association with 12-month MACE (p=0.516 
and p=0.675 respectively). Left main involvement was the only in-
dependent factor for 12-month MACE in baseline ApoB arm {3.77 
(1.015-14.014), p=0.047}. In-hospital complications included any 
of atrio-ventricular block, bradycardia, ventricular tachycardia, ven-
Table 2. Baseline characteristics, coronary angiographic findings and procedural results according to the levels of apolipoprotein B
Variables Group 1 (≤96.5 mg/dL), n=235 Group 2 (>96.5 mg/dL), n=235 p
Age (years) 66.5±11.4 63.2±12.5 0.032
Male gender (%) 130 (55.3) 122 (51.9) 0.459
Waist circumference (cm) 90.3±7.8 90.7±6.7 0.608
Body weight (kg) 65.8±12.6 66.1±12.0 0.792
Systolic blood pressure (mm Hg) 127.3±32.7 137.0±25.6 <0.001
Heart rate (beats/min) 74.9±21.6 78.6±17.9 0.05
Left ventricular ejection fraction (%) 54.7±12.7 53.9±11.5 0.59
Killip class >1 (%) 58 (24.7) 61 (26.0) 0.75
Smoking history (%) 81 (34.5) 89 (37.8) 0.523
Past history (%)
    Hypertension 187 (79.6) 170 (72.3) 0.067
    Diabetes mellitus 131 (55.7) 139 (59.1) 0.455
    Coronary artery disease 35 (14.9) 38 (16.2) 0.702
    Hyperlipidemia 10 (4.3) 6 (2.6) 0.309
Clinical presentation (%)
    ST-segment elevation myocardial infarction 148 (62.9) 132 (56.2) 0.124
Laboratory findings
    Glucose (mg/dL) 215.3±97.1 204.4±96.5 0.221
    Creatinine (mg/dL) 1.3±1.5 1.0±0.4 0.006
    Total cholesterol (mg/dL) 156.3±33.3 208.6±37.7 <0.001
    Triglycerides (mg/dL) 139.3±109.2 183.1±120.8 <0.001
    High density lipoprotein-cholesterol (mg/dL) 39.9±11.0 41.5±10.2 0.117
    Non-high density lipoprotein-cholesterol (mg/dL) 115.3±33.3 167.2±35.4 <0.001
    High sensitivity C-reactive protein (mg/dL) 3.4±4.9 2.4±3.8 0.015
    N terminal pro-brain natrieuretic peptide (pg/mL) 3660.5±6663.1 3149.6±5649.1 0.376
    Creatine kinase-MB (U/L) 101.5±104.7 105.7±102.2 0.659
    Troponin-I (ng/mL) 48.5±63.0 49.9±152.2 0.889
Angiographic findings, n (%)
    Multivessel involvement 83 (35.3) 84 (35.7) 0.709
    Left main involvement 16 (6.8) 6 (2.5) 0.035
    ACC/AHA lesion type C 65 (27.6) 63 (26.8) 0.882
    In-hospital complications 56 (23.8) 27 (11.5) 0.001
Discharge medications, n (%)
    Aspirin 224 (95.3) 225 (95.7) 0.230
    Clopidogrel 216 (91.9) 214 (91.0) 0.553
    Beta-blocker 190 (80.8) 191 (81.3) 0.608
    Calcium-channel blocker 31 (13.2) 23 (9.7) 0.275
    Anti-diabetic 101 (42.9) 102 (43.4) 0.829
    Statin  166 (70.6) 204 (86.8) <0.001
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tricular fibrillation, atrial fibrillation, cardiogenic shock, acute renal 
failure, metabolic acidosis/lactic acidosis, cerebrovascular event and/ 
or infection/sepsis. 
Follow-up patient analysis
A total of 306 out of 470 MS patients were followed up for 12 
months (follow-up rate 65.1%). They were also divided into 2 gr-
oups based on median values of non-HDL-C (104.7 mg/dL) and 
ApoB (76.05 mg/dL). Cox model showed no significant relation be-
tween 12-month MACE and follow-up non-HDL-C (p=0.205) or 
ApoB (p=0.831). N-terminal pro-brain natrieuretic peptide was the 
only independent predictor of 12-month MACE in non-HDL-C fol-
Table 3. Clinical outcomes at 12 months after percutaneous coronary intervention according to the baseline levels of non-high density lipoprotein-cho-
lesterol
Outcomes Group 1 (≤138 mg/dL), n=234 Group 2 (>138 mg/dL), n=236 Unadjusted p Linear p* Adjusted p
12-month MACE 17 (5.6) 15 (4.9) 0.595 0.714 0.516
12-month death  6 (1.9) 6 (1.9) 0.486 0.990 0.716
Data are expressed as number (percentage). *Means statistical significance for linear-by-linear association between categorical variables, which is calculat-
ed by chi-square test for trend. MACE: major adverse cardiac events 
Table 4. Clinical outcomes at 12 months after percutaneous coronary intervention according to the baseline levels of apolipoprotein B
Outcomes Group 1 (≤96.5 mg/dL), n=235 Group 2 (>96.5 mg/dL), n=235 Unadjusted p Linear p* Adjusted p
12-month MACE 16 (5.2) 16 (5.2) 0.698 0.958 0.675
12-month death  6 (1.9) 6 (1.9) 0.712 0.975 0.919
Data are number (percentage). *Means statistical significance for linear-by-linear association between categorical variables, which is calculated by chi-square 
test for trend. MACE: major adverse cardiac events 
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low-up arm {2.628 (1.025-6.738), p=0.044}. 
Fig. 1A and B show Cox adjusted survival curves for 12-month 
MACE of baseline and follow-up non-HDL-C respectively. Fig. 1C 
and D show Cox adjusted survival curves for 12-month MACE of 
baseline and follow-up ApoB respectively. 
Effect of rate of reduction of non-high density lipoprotein-
cholesterol and apolipoprotein B on clinical outcomes 
at 12-month
Reduction rate of non-HDL-C showed a decreasing trend of 12- 
month MACE, but it was not statistically significant {43.8% reduc-
tion in group A (0-10%) vs. 26.7% in group B (10-30%) vs. 19.0% 
in group C (>30%), p=0.069} as shown in Fig. 2. We noted that 12- 
month MACE also showed a decreasing trend as ApoB reduction 
rate increased {47.8% reduction in group A (0-10%) vs. 23.4% in 
group B (10-30%) vs. 16.2% in group C (>30%), p=0.004} as shown 
in Fig. 3. Prognostic value of the rates of ApoB reduction for 12- 
month MACE is presented in Table 5, when unadjusted showed 
significant relation with 12-month MACE (unadjusted p=0.012), 
59% reduction in group B {0.417 (0.191-0.907), p=0.027} and 67% 
reduction in group C {0.331 (0.157-0.695), p=0.003}. It was also sig-
nificant when adjusted with age and gender (Model 1), p=0.012, 
57% reduction in group B {0.437 (0.199-0.958), p=0.039} and 68% 
reduction in group C {0.324 (0.153-0.683), p=0.003}. After adjust-
ment with multiple covariates (Model 2), patients in group B had 
57% reduction {0.431 (0.186-0.997), p=0.049} and patients in gr-
oup C had 62% reduction {0.383 (0.171-0.855), p=0.019} for MACE 
at 12-month follow-up. The variables included in Model 2 were age, 
gender, creatinine, total cholesterol, triglyceride, Killip class, history 
of hyperlipidemia, clinical presentation with ST-elevation MI and 
ACC/AHA lesion type C. 
We further analyzed the patients with increase in ApoB level dur-
ing follow-up and found no significant association with 12-month 
MACE (unadjusted p=0.734 and adjusted p=0.43). Patients with 
increase in non-HDL-C were also found to have no significant as-
sociation with 12-month MACE during follow-up (unadjusted p= 
0.283 and adjusted p=0.744). Statin use was insignificant in both 
the arms (p=0.558 in non-HDL-C arm and p=0.789 in ApoB arm) 
during follow-up. 
Discussion
The present study demonstrated that higher non-HDL-C and ApoB 
levels in MS patients with AMI who underwent PCI showed no sig-
nificant association with 12-month MACE. There was positive cor-
relation between non-HDL-C and ApoB. ApoB was found to be a 
better predictor of 12-month MACE than non-HDL-C based on their 
reduction rates.
The prevalence of MS has reached epidemic proportions.
12) These 
patients are at three-fold greater risk of CAD and five-fold greater 
risk of cardiovascular mortality.
13) Dyslipidemia is a hallmark of MS 
and is characterized by elevation of triglyceride and low HDL-C. 
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Fig. 2. Non-HDL-C reduction rates vs. 12-month major adverse cardiac 
events. non-HCL-C: non-high density lipoprotein-cholesterol.
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Fig. 3. ApoB reduction rates vs. 12-month major adverse cardiac events. 
AopB: apolipoprotein B.
Table 5. Prognostic value of the rates of ApoB reduction for 12-month MACE
ApoB reduction group  ApoB reduction (%)
Hazard ratios (95% confidence interval)
No adjustment p Model 1
† p Model 2
‡ p
A (0-10)*
B (10-30) 0.417 (0.191-0.907) 0.027 0.437 (0.199-0.958) 0.039 0.431 (0.186-0.997) 0.049
C (>30)  0.331 (0.157-0.695) 0.003 0.324 (0.153-0.683) 0.003 0.383 (0.171-0.855) 0.019
*Reference group, 
†Adjusted for age and gender, 
‡Adjusted for age, gender, creatinine, total cholesterol, triglyceride, Killip class, history of hyperlipidemia, 
clinical presentation with ST-elevation MI and ACC/AHA lesion type C. ACC/AHA: American College of Cardiology/American Heart Association, ApoB: apoli-
poprotein B, MI: myocardial infarction, MACE: major adverse cardiac events 326  Non-HDL-C and ApoB in AMI Patients With Metabolic Syndrome 
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Plasma low density lipoprotein-cholesterol (LDL-C) is often found 
to be normal in these patients.
14) Non-HDL-C provides a measure 
of all ApoB-containing lipoproteins, all of which have the potential 
to deliver cholesterol into the arterial wall and contribute to ath-
erosclerotic lesions. This measure thus reflects atherogenic risk not 
captured by LDL-C measurement alone, particularly in the context 
of elevated triglyceride. Total serum ApoB is a strong predictor for 
severity of coronary atherosclerosis and CAD events, and non-
HDL-C is highly correlated with ApoB levels.
3) In Table 1 and 2, pa-
tients in group 1 were found to have lower levels of triglyceride. 
This might be by the definition of MS itself or due to older age, 
chronic kidney disease or may be influenced by heparin injection. 
We used fasting lipid levels after PCI for this analysis. The potential 
effect of heparin use on lipid levels might have influenced this 
study’s results. The fact that the incidence of in-hospital complica-
tions was higher in groups with lower non-HDL-C or ApoB. This 
could be attributed to older age, higher incidence of STEMI, let 
main artery disease, hypertension and also higher levels of serum 
creatinine and hs-CRP. 
Earlier studies demonstrated a ‘paradoxical’ decrease in mortality 
with a history of hypercholesterolemia.
3)15)16) The explanation for 
why hypercholesterolemia, unlike other cardiac risk factors, is par-
adoxically associated with better clinical outcomes remains ob-
scure. Rauchhaus et al.
15) suggested that survival, in general, is a 
result of balance of risks. Circulating lipoproteins play a potentially 
beneficial role by neutralizing lipopolysaccharides, which is a pos-
sible source of the immunologic activation in chronic heart failure. 
Cho et al.
17) studied the cholesterol paradox in AMI patients that 
showed higher LDL-C levels, except for patients with LDL-C ≥160 
mg/dL, were related to better clinical outcome after PCI. Another 
reason suggested for this paradox in patients with AMI is the im-
pact of statin treatment and the fact that previously diagnosed hy-
percholesterolemia is a marker for patients with more prior medical 
contact.
15) It is also known that obesity is a serious independent risk 
factor for CAD. But multiple studies have shown that obese CAD pa-
tients have better survival rate and have fewer cardiovascular events 
than normal-weight or underweight patients after PCI.
18-20) The rea-
son of this obesity paradox is unclear. According to previous hypoth-
esis normal and low body mass index (BMI) patients have small 
vessel size compared to obese. Consequently, they have smaller in-
travascular volume and poor compensation for a given amount of 
bleed. 
Previous AMI studies have shown a higher incidence of morbidity 
and mortality in older patients regardless of treatment options.
21)22) 
In our study, patients with higher non-HDL-C and ApoB levels were 
found to be younger. Younger age is most likely implicated in the 
confounded relation between higher BMI and AMI outcomes. This 
implies that AMI occurs at a younger age in the obese. It is this 
younger age that counterbalances the risks that DM, hypertension 
or dyslipidemia pose in the immediate course of care. As part of 
being younger, obese patients may have received more aggressive 
or attentive care.
19) Follow-up analysis also suggested that non-
HDL-C and ApoB had no relationship to clinical outcomes. Howev-
er, this might be due to lower follow-up rates that may lead to false 
negative results.
Non-high density lipoprotein-cholesterol has been proposed to be 
an acceptable surrogate of ApoB in routine clinical practice on the 
basis of the fact that they are highly correlated.
2)3) However, they 
do not measure the same thing: non-HDL-C is the mass of choles-
terol in the ApoB-containing lipoproteins, whereas ApoB is the 
number of atherogenic particles. The atherogenic risk resulting from 
lipoproteins does not relate primarily to their cholesterol content but 
rather to their size and number. In this regard, it is clearly important 
to examine whether ApoB is superior to non-HDL-C in its prediction 
of the risk of cardiovascular disease. 
The study by Pischon et al.
23) demonstrated that ApoB is superior 
to non-HDL-C to identify the risk of cardiovascular events. If ApoB 
and non-HDL-C are metabolically equivalent, they should keep the 
same biological company. But it is not so, ApoB is more closely asso-
ciated with increased BMI, abdominal obesity, hyperglycemia, insulin 
resistance, and pro-thrombogenic and pro-inflammatory markers 
than non-HDL-C.
24)25) In other words, ApoB relates more closely to 
the other features of the MS than non-HDL-C. On these grounds, 
ApoB, and not non-HDL-C, should be the pro-atherogenic index of 
choice in these patients.
26) Also, an earlier study in Korean popula-
tion demonstrated that ApoB is a better marker than non-HDL-C for 
identifying MS.
27) 
Incidence of each of cardiovascular death, MI, and repeated revas-
cularization were considered as components of MACE and not 
studied individually as it has long since been established that lipid 
profile and re-stenosis have no relationship. Cholesterol and obesity 
paradox may have some influence on the findings of our study and 
could explain the relation between higher non-HDL-C/ApoB and 
clinical outcomes. We suggest further randomized study with lon-
ger term follow-up of this finding to elucidate its role in MS patients 
with AMI after PCI. 
The present study should be interpreted in the light of the follow-
ing limitations. First, this is not a randomized trial, but a retrospec-
tive study. Second, patient population is relatively small but Cho et 
al.
17) studied cholesterol paradox in a large population with 9571 
AMI patients from the same registry and demonstrated similar re-
sults. Third, in the majority of cases blood samples for lipid profile 
were taken at least several hours (“overnight fasting blood”) after 
the onset of infarction. Therefore the non-HDL-C levels may be in-327 Khurshid Ahmed, et al.
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fluenced by infarction. Fourth, diurnal variations of ApoB and non-
HDL-C were not taken into consideration in our study. Fifth, heparin 
which is an integral part of treatment strategy in AMI setup may 
influence serum levels of non-HDL-C and ApoB. Sixth, the diagno-
sis of MS should be made using data obtained at least 8 weeks af-
ter AMI or surgery, because in the early course of AMI, levels of cho-
lesterols, glucose, and inflammatory markers are all altered, but we 
did not have exact 8 weeks data of all patients. 
In conclusion, 1) There was positive correlation between non-
HDL-C and ApoB. 2) There was no significant association between 
higher levels of either non-HDL-C or ApoB and 12-month MACE in 
MS patients with AMI undergoing PCI. 3) ApoB is a better predictor 
of MACE than non-HDL-C based on their reduction rates in this 
patient population. 
We suggest fully randomized long-term follow-up evaluation of 
our findings to reach a concrete conclusion.
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